sacituzumab govitecan-hziy
Gilead Sciences More Than Doubles Q1 Trodelvy Sales
The firm reported strong growth in revenues from its oncology segment, driven by the antibody-drug conjugate Trodelvy and CAR T-cell therapies Yescarta and Tecartus.
Gilead to Pursue Expanded Breast Cancer Indication for Trodelvy Following Phase III Data
Trodelvy reached its primary endpoint of improved progression-free survival for heavily pretreated HR-positive, HER2-negative metastatic breast cancer patients.
Gilead Sciences Q4 Cell Therapy Sales Increase 47 Percent
The firm's overall Q4 revenues decreased 2 percent year over year, but growth in the oncology segment remained strong.
AstraZeneca, Daiichi Sankyo Unveil First Datopotamab Deruxtecan TNBC Data at SABCS
The companies will conduct a Phase III trial of datopotamab deruxtecan following positive results from a Phase I TNBC cohort presented at the meeting.
European Commission Approves Gilead's Trodelvy for Metastatic TNBC
The EC approved Gilead's Trop-2 directed antibody drug conjugate for advanced, pretreated TNBC patients based on the results of the Phase III ASCENT study.